Stephenson Cancer Center | Strategic Alliance Partners

Latest from Stephenson Cancer Center

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 04, 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.